GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release through activation of the ghrelin receptor (GHS-R1a) and CD36 receptor. Developed in the 1980s as one of the first growth hormone secretagogues, it acts through a PKC/calcium-dependent pathway distinct from GHRH. Beyond GH release, GHRP-6 has demonstrated significant cardioprotective, wound healing, and cytoprotective properties in preclinical and early clinical research. It is notable for its strong appetite-stimulating effects via direct ghrelin receptor activation and its synergistic interaction with GHRH-class peptides.

• Growth Hormone Release
• Synergy with GHRH Peptides
• IGF-1 Elevation

Potent GH release, well-characterized pharmacokinetics in human studies, synergistic with GHRH-class peptides, established subcutaneous protocols

Subcutaneous injection provides rapid absorption with distribution half-life of ~7.6 minutes and elimination half-life of ~2.5 hours. Stimulates pulsatile GH release through GHS-R1a activation at pituitary and hypothalamic sites.

Peak plasma concentration: 15 min. Elimination half-life: 20 min. Largely cleared by: ~1.7 hrs.

Research protocols from published literature — not dosing recommendations.

• CJC-1295 — Synergistic: Strong synergy - GHRP-6 amplifies the GH pulse initiated by CJC-1295 through complementary receptor pathways (GHS-R1a + GHRH-R). Combined GH response is 2-3x greater than either alone. Well-established clinical combination.
• CJC-1295 with DAC — Use Caution: DAC version provides sustained GHRH stimulation (6-8 day half-life) which may lead to continuous GH elevation ("GH bleed") rather than pulsatile release when combined with GHRP-6. Pulsatile GH is preferred for mimicking natural physiology and avoiding receptor desensitization. Non-DAC CJC-1295 (Mod GRF 1-29) preferred for combination protocols.
• Ipamorelin — Use Caution: Both target GHS-R1a for GH release. Combination is redundant for GH stimulation—no additional GH benefit. Choose based on profile: GHRP-6 offers appetite stimulation and broader cytoprotective effects (via CD36 antagonism), while ipamorelin provides more selective GH release with minimal cortisol/prolactin elevation. Not unsafe, but therapeutically redundant.
• Hexarelin — Use Caution: Both are GHRP-class secretagogues acting on GHS-R1a. Hexarelin is a GHRP-6 derivative with 2-methyl-Trp substitution providing higher potency. Combination is redundant for GH stimulation and may amplify cortisol/prolactin side effects without proportional GH benefit. Choose one based on desired potency profile.
• MK-677 — Avoid Combination: MK-677 (ibutamoren) is an oral GHS-R1a agonist with a ~24-hour half-life, providing continuous ghrelin receptor stimulation. Combining with GHRP-6 creates redundant receptor activation with significantly amplified side effects (appetite, cortisol, prolactin elevation) without proportional GH benefit. Avoid combination due to side effect burden from sustained + pulsed receptor stimulation.
• BPC-157 — Compatible: Different mechanisms with no known interactions. BPC-157 focuses on tissue repair through distinct pathways. May complement recovery protocols.
• TB-500 — Compatible: Different mechanisms - TB-500 works through actin regulation and angiogenesis while GHRP-6 acts through GH release and ghrelin signaling. No known negative interactions.
• HGH — Monitor Combination: Exogenous HGH combined with GHRP-6 may produce excessive GH/IGF-1 levels. If combining, use lower doses of each and monitor IGF-1 levels. GHRP-6 stimulates endogenous GH which is preferable to exogenous for pulsatile release.
• Sermorelin — Synergistic: GHRH analog + GHRP creates the classic synergistic combination. Sermorelin stimulates via GHRH receptor while GHRP-6 acts through GHS-R1a for amplified pulsatile GH release.
• Insulin — Use Caution: GHRP-6 may increase blood glucose and reduce insulin sensitivity. Diabetic patients or those using insulin should monitor glucose closely and adjust doses under medical supervision.

Supplies:

• Bacteriostatic water (BAC water)
• Insulin syringes (29-31 gauge)
• Alcohol swabs
• GHRP-6 lyophilized powder vial

1. 1Allow vial to reach room temperature (15-20 minutes)
2. 2Clean vial top with alcohol swab and allow to dry
3. 3Calculate required bacteriostatic water volume using the calculator below
4. 4Draw calculated volume of bacteriostatic water into syringe
5. 5Inject water slowly down the inside wall of the vial (never directly onto powder)
6. 6Gently swirl until powder completely dissolves (never shake)
7. 7Solution should be clear - discard if cloudy or contains particles
8. 8Store reconstituted solution in refrigerator at 2-8°C

Immediately: Intense hunger within 15-20 minutes of injection, lasting 1-3 hours. Week 1-2: Improved sleep quality, increased appetite and food intake. Week 4-6: Changes in body composition (increased lean mass, reduced fat). Week 8-12: Peak effects on body composition and recovery. Side effects: Appetite increase (expected), mild cortisol/prolactin elevation, water retention. Hunger intensity may diminish after several weeks but does not fully resolve.

Proven safe in human Phase I dose-escalation clinical trial (IV administration). Causes significant appetite increase via ghrelin receptor activation - this is expected, not an adverse effect. Transiently elevates cortisol and prolactin at doses above 100mcg - usually not clinically significant. May increase blood glucose and reduce insulin sensitivity with prolonged use. Avoid use in active cancer - GH and IGF-1 elevation may promote tumor growth. Inject on empty stomach for optimal GH release - food blunts the response. Medical supervision recommended, particularly for those with diabetes or insulin resistance.

Proven safe in human Phase I dose-escalation clinical trial (IV administration). Causes significant appetite increase via ghrelin receptor activation - this is expected, not an adverse effect. Transiently elevates cortisol and prolactin at doses above 100mcg - usually not clinically significant. May increase blood glucose and reduce insulin sensitivity with prolonged use. Avoid use in active cancer - GH and IGF-1 elevation may promote tumor growth. Inject on empty stomach for optimal GH release - food blunts the response. Medical supervision recommended, particularly for those with diabetes or insulin resistance.

GHRP-6 should be stored at Refrigerate at 2-8°C, use within 30 days after reconstitution.